Price action starting to look unconvincing - it hasn't breached any significant overhead levels to engender any bullish sentiment. This FDA narrative seems a tad desperate. Long term, does little to elicit confidence given the headwinds the company faces externally and from within.
If this revisits $4 I think further downside and new lows are likely.
Just can't see past management on this one; not a good team at the helm.
Price action starting to look unconvincing - it hasn't breached...
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.06 |
Change
0.070(1.17%) |
Mkt cap ! $4.380B | |||
| Open | High | Low | Value | Volume |
| $5.99 | $6.11 | $5.96 | $11.09M | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6819 | $6.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.06 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.06 |
Change
0.070 ( 1.12 %) |
||||
| Open | High | Low | Volume | ||
| $5.97 | $6.11 | $5.95 | 810802 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| A2M (ASX) Chart |